What's in Allist Pharmaceuticals, Inc.'s pipeline?

Allist Pharmaceuticals, Inc. has 11 drugs in our index: 0 marketed, 0 filed, 5 in Phase 3, 0 in Phase 2, 5 in Phase 1.

Which companies overlap with Allist Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals Co., Ltd., Caliway Biopharmaceuticals Co., Ltd., Beta Pharma Shanghai, Eisai Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/allist-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Allist Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Allist Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 0 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
JAB-3312	JAB-3312	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology
Firmonertinib Mesilate Tablets	Firmonertinib Mesilate Tablets	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (Epidermal Growth Factor Receptor)	Oncology
JAB-21822	JAB-21822	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology
Pemetrexed Disodium for Injection	Pemetrexed Disodium for Injection	phase 3	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase	Oncology
Furmonertinib Mesilate Tablets	Furmonertinib Mesilate Tablets	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)	Oncology

Therapeutic area mix

Oncology · 5
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
Caliway Biopharmaceuticals Co., Ltd. · 1 shared drug class
Beta Pharma Shanghai · 1 shared drug class
Eisai Inc. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Bayer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Allist Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Allist Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/allist-pharmaceuticals-inc. Accessed 2026-05-16.